Anti-CD137 + Anti-CTLA-4 Monoclonal Antibodies for Advanced Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This study is an open-label, Phase 1, multicenter study to evaluate the safety, tolerability, PK, and PD profiles of AGEN2373 as a monotherapy and in combination with botensilimab (also known as AGEN1181), and to assess the maximum tolerated dose (MTD) in subjects with advanced solid tumors.
Who Is on the Research Team?
Medical Monitor
Principal Investigator
Agenus Inc.
Are You a Good Fit for This Trial?
Adults with advanced solid tumors that have spread or are inoperable, and who've had no success with standard treatments. They must be healthy enough overall, not pregnant, willing to use contraception, and able to provide a recent tumor tissue sample. People can't join if they've recently received certain vaccines or treatments, have severe allergies to human antibodies, uncontrolled health issues like heart disease or infections, mental incapacity, or are pregnant.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive AGEN2373 as monotherapy or in combination with botensilimab, with dose escalation to determine the maximum tolerated dose
Follow-up
Participants are monitored for safety and effectiveness after treatment
Open-label extension (optional)
Participants may opt into continuation of treatment long-term
What Are the Treatments Tested in This Trial?
Interventions
- AGEN1181
- AGEN2373
- Botensilimab
Find a Clinic Near You
Who Is Running the Clinical Trial?
Agenus Inc.
Lead Sponsor